Showing all 8 results
Amlodipine & Enalapril Maleate Tablets
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets to protect the Enalapril Maleate from moisture-induced degradation and to ensure the physical integrity of the combination.
Active Ingredient Strength (Standard) Therapeutic Role Amlodipine (as Besylate) BP/USP 5 mg / 10 mg Calcium Channel Blocker (CCB) Enalapril Maleate BP/USP 5 mg / 10 mg / 20 mg ACE Inhibitor Excipients Q.S. Sodium Stearyl Fumarate / Lactose Lubricant & Stabilizer Amlodipine Besylate & Losartan Potassium Tablets
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets. The formulation is optimized for 24-hour efficacy, allowing for convenient once-daily dosing.
Active Ingredient Strength (Standard) Therapeutic Role Amlodipine Besylate BP/USP 5 mg Calcium Channel Blocker (CCB) Losartan Potassium BP/USP 50 mg Angiotensin Receptor Blocker (ARB) Excipients Q.S. Microcrystalline Cellulose / Starch Stabilizing Core Matrix Atenolol & Chlorthalidone Tablets
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets. The combination is engineered to maintain therapeutic plasma levels over a 24-hour period, supporting once-daily dosing.
Active Ingredient Strength (Standard) Therapeutic Role Atenolol BP/USP 50 mg / 100 mg Cardioselective Beta-Blocker Chlorthalidone BP/USP 12.5 mg / 25 mg Long-acting Diuretic Excipients Q.S. Magnesium Stearate / Povidone Stabilizing Core Matrix Lisinopril Tablet
FreeProduct Composition & Available Portfolio Range
We manufacture Lisinopril in exact, compendial strengths calibrated to support initial introductory titration up to high-potency cardioprotective maintenance blocks.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Lisinopril Anhydrous / Dihydrate USP / BP / IP 5 mg Oral Solid Uncoated Tablet Initial Titration: For low-dose introductory management, pediatric hypertension, or initial combination therapy initiation. Lisinopril Anhydrous / Dihydrate USP / BP / IP 10 mg Oral Solid Uncoated Tablet Core Commercial Volume: Standard international baseline daily dose for mild-to-moderate chronic essential hypertension. Lisinopril Anhydrous / Dihydrate USP / BP / IP 20 mg Oral High-Potency Solid Tablet Advanced Cardioprotection: High-strength configuration calibrated for severe heart failure management and post-infarction survival optimization. Losartan Tablet
FreeProduct Composition & Available Strengths
We supply Losartan Potassium across the complete, internationally recognized therapeutic range to facilitate progressive dose titrations and precise maintenance regimens.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Losartan Potassium USP / BP / IP 25 mg Oral Solid Film-Coated Tablet Pediatric & Low-Dose Titration: For introductory pediatric hypertension care or initial combination-therapy building. Losartan Potassium USP / BP / IP 50 mg Oral Solid Film-Coated Tablet Core Commercial Volume: Standard international baseline daily dose for mild-to-moderate chronic essential hypertension. Losartan Potassium USP / BP / IP 100 mg Oral High-Potency Solid Tablet Maximal Saturation Maintenance: For advanced hypertensive management, diabetic nephropathy progression delay, and stroke risk reduction in left ventricular hypertrophy. Methyldopa Tablet
FreeProduct Composition & Available Strengths
We supply Methyldopa in standard, exact strengths designed to facilitate the careful, progressive dose titration required in gestational healthcare.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Methyldopa Anhydrous IP / BP / USP 250 mg Oral Solid Film-Coated Tablet (Scored for micro-titration) Initial Titration / Baseline Care: For early-stage gestational hypertension and lower-dose fine-tuning. Methyldopa Anhydrous IP / BP / USP 500 mg Oral Solid Film-Coated Tablet (Engineered for uniform mass release) High-Potency Maintenance: For advanced chronic hypertension during pregnancy and severe pre-eclamptic stabilization. Nifedipine Tablet
FreeProduct Composition & Structural Formats
We manufacture Nifedipine across the complete clinical dosage spectrum, utilizing distinct release matrices calibrated for immediate stabilization or sustained, once-daily therapeutic coverage.
Active Ingredient Available Strengths Formulation Matrix Delivery System Primary Clinical Focus Nifedipine IP/BP/USP 10 mg Immediate-Release / Rapid-Onset Film Tablet Acute Titration / Tocolysis: For severe acute hypertension or suppression of premature labor contractions. Nifedipine IP/BP/USP 20 mg Sustained-Release (SR) Retard Matrix Twice-Daily Maintenance: Intermediate control for stable chronic hypertension. Nifedipine IP/BP/USP 30 mg Once-Daily Extended-Release (XR / XL) Matrix First-Line Chronic Care: Continuous 24-hour plasma stabilization for mild-to-moderate hypertension. Nifedipine IP/BP/USP 60 mg Once-Daily Extended-Release (XR / XL) Matrix High-Potency Control: For refractory essential hypertension and severe chronic stable angina pectoris. Nifedipine Tablet
FreeProduct Composition & Structural Formats
We supply Nifedipine in exact, internationally standardized strengths, optimized for immediate-release emergency titration or controlled-release daily maintenance.
Active Ingredient Available Strengths Formulation Mechanism Primary Clinical Target Nifedipine IP / BP / USP 10 mg Immediate or Modified Release Acute Titration / Tocolysis: For rapid blood pressure adjustment or suppression of premature labor. Nifedipine IP / BP / USP 20 mg Sustained / Retard Matrix Daily Maintenance: Continuous 12-to-24-hour plasma concentration for chronic hypertension and angina.
